Who are the top shareholders of the Amwill?

The top shareholders of Amwill include promoter Anand Gandhi with 31.64%, two Foreign Institutional Investors holding 1.16%, and public shareholder Varun Krishnavtar Kabra with 2.86%. Individual investors own 21.14% of the shares, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Amwill include the promoters, who hold the majority of the shares. The promoter with the highest holding is Anand Gandhi, owning 31.64% of the company. Additionally, there are two Foreign Institutional Investors (FIIs) that collectively hold 1.16%. The highest public shareholder is Varun Krishnavtar Kabra, with a stake of 2.86%. Individual investors also hold a significant portion, accounting for 21.14% of the shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

Has Amwill declared dividend?

No Dividend History Available

Who are the peers of the Amwill?

Amwill's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Management risk varies from excellent to average among peers, with Divi's Lab showing the highest 1-year return at 51.88% and Smruthi Organic the lowest at -22.54%.

Peers: The peers of Amwill are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Krebs Biochem, Auro Labs., Bal Pharma, Smruthi Organic, and Aarey Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amwill, Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Auro Labs., and Smruthi Organic, while Good management risk is found at Divi's Lab., Torrent Pharma, Bal Pharma, and Aarey Drugs. Average management risk is noted at Bal Pharma, and the rest have either below average or do not qualify. Growth is excellent at Amwill, Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is seen at Divi's Lab., Torrent Pharma, Auro Labs., and Smruthi Organic. Average growth is noted at Bal Pharma, and the rest do not qualify.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.88%, while Smruthi Organic has the lowest at -22.54%. Amwill's 1-year return is not available for comparison. Additionally, Krebs Biochem and Smruthi Organic have negative six-month returns.

What does Amwill Health do?

Amwill Health Care Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology sector, was incorporated in 2017 and became a Public Limited Company in 2024. It has a market cap of INR 133 Cr, with a P/E ratio of 13.00 and a return on equity of 62.53%.

Overview:<BR>Amwill Health Care Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>Amwill Health Care Ltd was originally incorporated on August 21, 2017, under the name 'Amwill Health Care Private Limited'. The company transitioned to a Public Limited Company, receiving a fresh Certificate of Incorporation on January 25, 2024, with the name change to 'Amwill Health Care Limited'. Revenue and profit data are not available for any specific quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 133 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 13.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.19<BR>Return on Equity: 62.53%<BR>Price to Book: 7.75<BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A<BR>Email: N/A<BR>Website: N/A

How big is Amwill Health?

As of 24th July, Amwill Health Care Ltd has a market capitalization of 134.00 Cr, classified as a Micro Cap, with no valid financial data available for Net Sales and Net Profit for the latest four quarters. As of March 2025, Shareholder's Funds are 69.22 Cr and Total Assets are 71.26 Cr.

As of 24th July, <BR><BR>Market Cap: Amwill Health Care Ltd has a market capitalization of 134.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 69.22 Cr and Total Assets at 71.26 Cr.

When is the next results date for Amwill Health?

Amwill Health will announce its results on November 4, 2025.

Amwill Health is scheduled to declare its results on November 4, 2025.

How has been the historical performance of Amwill Health?

Amwill Health's historical performance shows fluctuating financial metrics, with net sales rising to 43.95 Cr in Mar'24 before declining to 40.58 Cr in Mar'25. Despite growth in total assets and improved cash flow, profitability metrics such as operating profit and profit after tax decreased in the latest fiscal year.

Answer:<BR>The historical performance of Amwill Health shows a fluctuating trend in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Amwill Health's net sales increased from 27.61 Cr in Mar'22 to 43.95 Cr in Mar'24, before declining to 40.58 Cr in Mar'25. Total operating income followed a similar pattern, rising to 43.95 Cr in Mar'24 and then decreasing to 40.58 Cr in Mar'25. The total expenditure also rose from 23.95 Cr in Mar'22 to 28.93 Cr in Mar'25. Operating profit, excluding other income, peaked at 16.67 Cr in Mar'24 but fell to 11.65 Cr in Mar'25. Profit before tax showed a similar decline from 16.76 Cr in Mar'24 to 11.90 Cr in Mar'25, while profit after tax decreased from 12.50 Cr to 10.73 Cr in the same period. The company's total assets grew significantly from 12.29 Cr in Mar'23 to 71.26 Cr in Mar'25, indicating a strong increase in shareholder's funds, which rose to 69.22 Cr by Mar'25. Cash flow from operating activities improved to 5.00 Cr in Mar'25, contrasting with a negative cash flow of -3.00 Cr in Mar'24. Overall, while Amwill Health experienced growth in assets and operating cash flow, its profitability metrics showed a decline in the most recent fiscal year.

Is Amwill Health overvalued or undervalued?

As of November 7, 2025, Amwill Health is considered undervalued with a PE ratio of 9.06 and strong return metrics, making it an attractive investment compared to peers like Sun Pharma and Dr Reddy's Labs.

As of 7 November 2025, Amwill Health's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued, with a PE ratio of 9.06, an EV to EBIT of 7.64, and an EV to EBITDA of 7.34. These ratios suggest that Amwill Health is trading at a discount compared to its peers in the pharmaceuticals and biotechnology sector.<BR><BR>In comparison, Sun Pharma is considered expensive with a PE ratio of 35.17, while Dr Reddy's Labs is attractive with a PE ratio of 17.43. This peer comparison highlights Amwill Health's favorable valuation position. Additionally, the company's return metrics are strong, with a ROCE of 18.23% and a ROE of 14.68%, further supporting the undervaluation narrative. Despite recent stock performance lagging behind the Sensex, the overall valuation suggests a compelling investment opportunity in Amwill Health.

Which are the latest news on Amwill Health?

Why is Amwill Health falling/rising?

As of 04-Dec, Amwill Health Care Ltd's stock price is Rs. 40.00, down 4.63%, marking a significant decline of 28.35% over the past month. The stock is underperforming compared to the Sensex and has hit a new 52-week low, reflecting bearish investor sentiment and reduced trading interest.

As of 04-Dec, Amwill Health Care Ltd's stock price is falling, currently at Rs. 40.00, which represents a decrease of Rs. 1.94 or 4.63%. The stock has been underperforming significantly, with a decline of 5.90% over the past week, while the benchmark Sensex has only decreased by 0.53%. Over the last month, the stock has experienced a substantial drop of 28.35%, contrasting sharply with the Sensex's gain of 2.16%.<BR><BR>Today's performance indicates that the stock has hit a new 52-week low of Rs. 40, and it has been on a consecutive downward trend for the last three days, accumulating a total loss of 6.93% during this period. The stock opened with a gap down of 3.31% today and reached an intraday low of Rs. 40, reflecting ongoing bearish sentiment among investors.<BR><BR>Additionally, Amwill Health is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a persistent downward trend. Investor participation has also declined, with delivery volume dropping by 25% compared to the 5-day average, indicating reduced interest in the stock. Overall, these factors contribute to the stock's falling price.